RxDoctor Payments DataLook up a doctor →

Daniel Norman, MD

Sleep Medicine · Los Angeles, CANPI 1730198730

Payments from drug & device makers

$4,205,767in general payments, 2019–2025

Across 805 payments — averaging $5224.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$3.5M
  • Harmony Biosciences LLC$225K
  • Jazz Pharmaceuticals Inc.$214K
  • Alkermes, Inc.$155K
  • Avadel CNS Pharmaceuticals, LLC$52K
  • Takeda Pharmaceuticals U.S.A., Inc.$19K
  • plus $14K from 19 others
$8,622in research payments, 2019–2025

Across 7 payments — averaging $1231.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Harmony Biosciences LLC$9K
  • GSK$73

What the payments were for

  • Consulting fees$9,15439%
  • Speaking & faculty fees$5,40023%
  • Travel & lodging$8674%
  • Food & beverage$7,91733%
  • Education$3501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,205,767 in reported general payments places this provider in the 95th percentile of 200 sleep medicine providers in California.

See all sleep medicine providers in California

Medicare billing

Part B allowed, 2024
$465,784
Medicare patients
1,261
Services billed
2,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate14$301,218
LumryzSodium Oxybate12$139,447
DayvigoLemborexant54$21,357
BelsomraSuvorexant37$16,720
QuviviqDaridorexant Hcl24$11,230
Mirtazapine63$2,236
Zolpidem Tartrate38$1,503
Azelastine Hcl40$1,409
Modafinil33$1,231
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$1,005
Ramelteon18$879
Acetazolamide21$689
Armodafinil18$382
Fluticasone Propionate23$377
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avadel CNS Pharmaceuticals, LLCLumryz$51,688$139,44712 claims
Eisai Inc.Dayvigo$746$21,35754 claims
MerckBelsomra$118$16,72037 claims
Idorsia Pharmaceuticals US IncQuviviq$171$11,23024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 200 sleep medicine providers in California.

Other sleep medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →